Geriatric characteristics in randomised controlled trials on antidepressant drugs for older adults: a systematic review

International Journal of Geriatric Psychiatry

Volumn 31, Issue 9, 2016, Pages 990-1003

  Benraad, Carolien E M ^a,b   Kamerman Celie, Floor ^b   van Munster, Barbara C ^b,c   Oude Voshaar, Richard C ^d   Spijker, Jan ^e,f   Olde Rikkert, Marcel G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Pro Persona Mental Health Care ^*  (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e Mental Health Care   (Netherlands)

^f RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

aged; antidepressant drug; co morbidity; cognitive function; disability; frailty; geriatric syndrome; major depressive disorder; malnutrition

Indexed keywords

ANTIDEPRESSANT AGENT;

COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DISABILITY; DISEASE DURATION; DISEASE SEVERITY; FALLING; FRAIL ELDERLY; FUNCTIONAL STATUS; GERIATRIC DISORDER; HUMAN; LATE LIFE DEPRESSION; MAJOR DEPRESSION; MALNUTRITION; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT CHANGE;

EID: 84982166096     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4443     Document Type: Review

References (82)

1. Wilson K. 2009. Antidepressants versus plac depressed elderly Coch Libr.pdf.
2. Allard P, Gram L, Timdahl K, et al. 2004. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 19: 1123–1130.
3. Baldwin R, Jeffries S, Jackson A, et al. 2004. Treatment response in late-onset depression: relationship to neuropsychological, neuroradiological and vascular risk factors. Psychol Med 34: 125–136.
4. Beekman AT, Copeland JR, Prince MJ. 1999. Review of community prevalence of depression in later life. Br J Psychiatry 174: 307–311.
5. Beekman AT, Penninx BW, Deeg DJ, et al. 1997. Depression and physical health in later life: results from the Longitudinal Aging Study Amsterdam (LASA). J Affect Disord 46: 219–231.
6. Benraad CE, Hilderink PH, Van Driel DT, et al. 2013. Physical functioning in older persons with somatoform disorders: a pilot study. J Am Med Dir Assoc 14: 75.e9–75.e13.
7. Bogner HR, Cary MS, Bruce ML, et al. 2005. The role of medical comorbidity in outcome of major depression in primary care: the PROSPECT study. Am J Geriatr Psychiatry 13: 861–868.
8. Bondareff W, Alpert M, Friedhoff AJ, et al. 2000. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 157: 729–736.
9. Bose A, Li D, Gandhi C. 2008. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 16: 14–20.
10. Calati R, Salvina Signorelli M, Balestri M, et al. 2013. Antidepressants in elderly: metaregression of double-blind, randomized clinical trials. J Affect Disord 147: 1–8.
11. Chapman IM. 2012. The anorexia of ageing. In Pathy's Principles and Practice of Geriatric Medicine, Sinclair AJ, Morley JE, Vellas B (eds.). 5th edn.Wiley-Blackwell: Chichester, United Kingdom.
12. Chen YM, Huang XM, Thompson R, Zhao YB. 2011. Clinical features and efficacy of escitalopram treatment for geriatric depression. J Int Med Res 39: 1946–1953.
13. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. 2013. Frailty in elderly people. The Lancet 381: 752–762.
14. Cole MG, Dendukuri N. 2003. Risk factors for depression among elderly community subjects: a systematic review and meta-analysis. Am J Psychiatry 160: 1147–1156.
15. Collard RM, Comijs HC, Naarding P, Oude Voshaar RC. 2014. Physical frailty: vulnerability of patients suffering from late-life depression. Aging Ment Health 18: 570–578.
16. Dalery J, Aubin V. 2001. Comparative study of paroxetine and mianserin in depression in elderly patients: efficacy, tolerance, serotonin dependence. Encéphale 27: 71–81.
17. De Wit LM, Van Straten A, Van Herten M, Penninx BW, Cuijpers P. 2009. Depression and body mass index, a u-shaped association. BMC Public Health 9: 14.
18. Djernes JK. 2006. Prevalence and predictors of depression in populations of elderly: a review. Acta Psychiatr Scand 113: 372–387.
19. Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH. 1987. Clinical management – clomipramine / placebo administration manual. Psychopharmacol Bull 23: 309–324.
20. Feng L, Nyunt MS, Feng L, Yap KB, Ng TP. 2014. Frailty predicts new and persistent depressive symptoms among community-dwelling older adults: findings from Singapore longitudinal aging study. J Am Med Dir Assoc 15: 76 e7–76 e12.
21. Forlenza OV, Almeida OP, Stoppe A Jr, Hirata ES, Ferreira RCR. 2001. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Int Psychogeriatr 13: 75–84.
22. Fraguas R, Da Silva Telles RM, Alves TCTF, et al. 2009. A double-blind, placebo-controlled treatment trial of citalopram for major depressive disorder in older patients with heart failure: the relevance of the placebo effect and psychological symptoms. Contemp Clin Trials 30: 205–211.
23. Gasto C, Navarro V, Marcos T, et al. 2003. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol 23: 21–26.
24. Giron MS, Fastbom J, Winblad B. 2005. Clinical trials of potential antidepressants: to what extent are the elderly represented: a review. Int J Geriatr Psychiatry 20: 201–217.
25. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56–62.
26. Heo M, Papademetriou E, Meyers BS. 2009. Design characteristics that influence attrition in geriatric antidepressant trials: meta-analysis. Int J Geriatr Psychiatry 24: 990–1001.
27. Heun R, Ahokas A, Boyer P, et al. 2013. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry 74: 587–594.
28. Hewett K, Chrzanowski W, Jokinen R, et al. 2010. Double-blind, placebo-controlled evaluation of extended-release bupropion in elderly patients with major depressive disorder. J Psychopharmacol 24: 521–529.
29. Higgins JPT, Green S. 2011. Cochrane Handbook for systematic reviews of interventions version 5.1.0, The Cochrane Collaboration [March 2011] www.cochrane-handbook.org [Online]. [Accessed March 2011.
30. Inouye SK, Studenski S, Tinetti ME, Kuchel A. 2007. Geriatric syndromes: clinical, research and policy implications of a core geriatric concept. J Am Geriatr Soc 55: 780–791.
31. Kasper S, De Swart H, Andersen HF. 2005. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatr 13: 884–891.
32. Katon WJ, Lin EHB, Von Korff M, et al. 2010. Collaborative care for patients with depression and chronic medical illness. N Engl J Med 363: 2611–2620.
33. Katona C, Hansen T, Olsen CK. 2012. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol 27: 215–223.
34. Koenig HG, George LK, Peterson BL, Pieper CF. 1997. Depression in medically ill hospitalised older adults: prevalence, characteristics, and course of symptoms according to six diagnostic schemes. Am J Psychiatry 154: 1376–1783.
35. Kok RM, Nolen WA, Heeren TJ. 2007. Venlafaxine versus nortriptyline in the treatment of elderly depressed inpatients: a randomised, double-blind, controlled trial. Int J Geriatr Psychiatry 22: 1247–1254.
36. Kok RM, Nolen WA, Heeren TJ. 2012. Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants. J Affect Disord 141: 103–115.
37. Lenze E, Rogers J, Martire L, et al. 2001. The association of late-life depression and anxiety with physical disability, a review of the literature and prospectus for future research. Am J Geriatr Psychiatr 9: 113–135.
38. Leon AC, Mallinckrodt CH, Chuang-Stein C, et al. 2006. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biol Psychiatry 59: 1001–1005.
39. Levine J, Schooler NR. 1986. SAFTEE: a Technique for the systematic assessement of side effects in clinical trials. Psychopharmacol Bull 22: 343–380.
40. Limosin F, Samuelian JC, Rouillon F. 2006. Multicenter double-blind study of the efficacy of paroxetine versus clomipramine in elderly patients with major depression. J Aging Pharmacother 13: 7–19.
41. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. 1987. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 76(suppl 334): 1–100.
42. Locher C, Kossowsky J, Gaab J, et al. 2015. Moderation of antidepressant and placebo outcomes by baseline severity in late-life depression: a systematic review and meta-analysis. J Affect Disord 181: 50–60.
43. Loudon K, Treweek S, Sullivan F, et al. 2015. The PRECIS-2 tool: designing trials that are fit for purpose. BMJ 350: h2147.
44. Luppa M, Sikorski C, Luck T, el al. 2012. Age- and gender-specific prevalence of depression in latest-life – systematic review and meta-analysis. J Affect Disord 136: 212–221.
45. Mcmurdo ME, Roberts H, Parker S, et al. 2011. Improving recruitment of older people to research through good practice. Age Ageing 40: 659–665.
46. Mezuk B, Lohman M, Dumenci L, Lapane KL. 2013. Are depression and frailty overlapping syndromes in mid- and late-life? A latent variable analysis. Am J Geriatr Psychiatry 21: 560–569.
47. Miller M, Paradis C, Houck P, et al. 1992. Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 41: 237–248.
48. Montgomery SA, Asberg M. 1979. A new depression scale designed to be sensitive to change. Br J Psychiatry 134: 382–389.
49. Mulsant BH, Pollock BG, Nebes R, et al. 2001. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry 9: 406–414.
50. Navarro V, Gasto C, Torres X, Marcos T, Pintor L. 2001. Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study. Acta Psychiatr Scand 103: 435–440.
51. Nelson JC, Delucucchi K, Schneider LS. 2008. Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence. Am J Ger Psychiatry 558–567.
52. Newhouse PA, Krishnan KRR, Doraiswamy PM, et al. 2000. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 61: 559–568.
53. Oslin D, Datto C, Kallan M, et al. 2002. Association between medical comorbidity and treatment outcomes in late-life depression. J Am Geriatr Soc 50: 823–828.
54. Penninx BJW, Milaneschi Y, Lamers F, Vogelzangs N. 2013. Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 11: 129.
55. Rapaport MH, Lydiard RB, Pitts CD, et al. 2009. Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. J Clin Psychiatry 70: 46–57.
56. Rapaport MH, Schneider LS, Dunner DL, Davies JT, Pitts CD. 2003. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry 64: 1065–1074.
57. Raskin J, Wiltse CG, Siegal A, et al. 2007. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. J Clin Psychiatry 164: 900–909.
58. Reuben DB, Tinetti ME. 2012. Goal-oriented patient care – an alternative health outcomes paradigm. N Engl J Med 366: 777–779.
59. Robinson M, Oakes TM, Raskin J, et al. 2014. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo. Am J Geriatr Psychiatry 22: 34–45.
60. Roose SP, Sackeim HA, Krishnan KRR, et al. 2004. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry 161: 2050–2059.
61. Rutherford BR, Tandler J, Brown PJ, Sneed JR, Roose SP. 2014. Clinic visits in late-life depression trials: effects on signal detection and therapeutic outcome. Am J Geriatr Psychiatry 22: 1452–1461.
62. Saka B, Kaya O, Ozturk GB, Erten N, Karan MA. 2010. Malnutrition in the elderly and its relationship with other geriatric syndromes. Clin Nutr 29: 745–748.
63. Schatzberg A, Roose S. 2006. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 14: 361–370.
64. Schatzberg AF, Kremer C, Rodrigues HE, et al. 2002. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 10: 541–550.
65. Schneider LS, Nelson JC, Clary CM, et al. 2003. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 160: 1277–1285.
66. Sheehan D, Harnett-Sheehan K, Rai B. 1996. The measurement of disability. Int Clin Psychopharmacol 11(suppl 3): 89–95.
67. Sheikh JI, Cassidy EL, Doraiswamy PM, et al. 2004. Efficacy, safety, and tolerability of sertraline in patients with late-life depresson and comorbid medical illness. J Am Geriatr Soc 52: 86–92.
68. Slymen DJ, Drew JA, Elder JP, Williams SJ. 1996. Determinants of non-compliance and attrition in the elderly. Int J Epidemiol 25: 411–419.
69. Straus SE, Glasziou P, Richardson WS, Haynes RB. 2011. Evidence-based Medicine: How to Practice and Teach It. Churchill, Linvingstone, Elsevier: Edinburgh.
70. Taylor WD, Aizenstein HJ, Alexopoulos GS. 2013. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry 18: 963–974.
71. Taylor WD, Steffens DC, Macfall JR, et al. 2003. White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry 60: 1090–1096.
72. Tedeschini E, Levkovitz Y, Iovieno N, et al. 2011. Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry 72: 1660–1668.
73. Thombs BD, Ziegelstein RC, Pilote L, et al. 2010. Somatic symptom overlap in Beck Depression Inventory-II scores following myocardial infarction. Br J Psychiatry 197: 61–66.
74. Thorlund K, Druyts E, Wu P, et al. 2015. Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc 63: 1002–1009.
75. Trick L, Stanley N, Rigney U, Hindmarch I. 2004. A double-blind, randomized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75 mg (37.5 mg b.i.d.) venlafaxine and 75 mg (25 mg mane, 50 mg nocte) dothiepin in elderly patients with moderate major depression being treated in general practice. J Psychopharmacol 18: 205–214.
76. Vellas B, Guigoz Y, Garry PJ, et al. 1999. The Mini Nutritional Assessment (MNA) and its use in grading the nutritional state of elderly patients. J Nutr Health Aging 15: 116–122.
77. Ware J, Sherbourne C. 1992. The MOS 36-item Short-Form Health Survey (SF-36) I. Conceptual framework and item selection. Med Care 30: 473–483.
78. Watts G. 2012. Why the exclusion of older people from clinical research must stop. BMJ 344: e3445.
79. Weihs KL, Settle JR, Batey EC. 2000. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. Am J Psychiatry 61: 196–202.
80. Wilson K, Mottram PG, Nightingale A. 2001. Antidepressants versus placebo for the depressed elderly (review). The Cochrane Collaboration.
81. Wise TN, Wiltse CG, Iosifescu DV, et al. 2007. The safety and tolerability of duloxetine in depressed elderly patients with and without medical comorbidity. Int J Clin Pract 61: 1283–1293.
82. Wohlreich MM, Sullivan MD, Mallinckrodt CH, et al. 2009. Duloxetine for the treatment of recurrent major depressive disorder in elderly patients: treatment outcomes in patients with comorbid arthritis. Psychosomatics 50: 402–412.